Here, we demonstrate that the inhibition of LDHA and GLS1—two metabolic targets that are currently under investigations in clinical trials for cancer therapy—impairs anti-CD40 monoclonal antibody-induced antitumor responses. This evidence concerns the gene CD40 and cancer.